Carmell Corp
NASDAQ:CTCX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Carmell Corp
NASDAQ:CTCX
|
US |
|
A
|
Automotive Stampings and Assemblies Ltd
NSE:ASAL
|
IN |
|
T
|
Topcon Corp
OTC:TOPCF
|
JP |
|
Corporacion Actinver SAB de CV
BMV:ACTINVRB
|
MX |
|
X
|
Xinjiang Tianfu Energy Co Ltd
SSE:600509
|
CN |
|
Sanvo Fine Chemicals Group Ltd
HKEX:301
|
CN |
|
N
|
Nemetschek SE
DUS:NEM
|
DE |
|
Territorial Bancorp Inc
NASDAQ:TBNK
|
US |
|
N
|
Namchow Food Group Shanghai Co Ltd
SSE:605339
|
CN |
|
Natural Grocers By Vitamin Cottage Inc
NYSE:NGVC
|
US |
|
Rath AG
LSE:0FRT
|
AT |
|
Enterprise Financial Services Corp
NASDAQ:EFSC
|
US |
|
Nam.R SA
PAR:ALNMR
|
FR |
|
Cooper Energy Ltd
ASX:COE
|
AU |
|
Ambu A/S
OTC:AMBFF
|
DK |
|
Australia and New Zealand Banking Group Ltd
ASX:ANZ
|
AU |
|
Vitec Group Plc
LSE:VTC
|
UK |
|
SORIL Infra Resources Ltd
NSE:SORILINFRA
|
IN |
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
NO |
|
E
|
Elicera Therapeutics AB
STO:ELIC
|
SE |
Carmell Corp
Carmell Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 10 full-time employees. The company went IPO on 2021-07-29. Carmell Corporation, formerly Carmell Therapeutics Corporation, is a regenerative medicine platform company. The firm is engaged in the development of allogeneic plasma-based bioactive material (PBM) that is designed to boost innate regenerative pathways across a variety of bone and soft tissue indications. The PBM technology is licensed from Carnegie Mellon University and claims the ability to plasticize whole plasma and cross link with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. Its lead product, CT-101 Bone Healing Accelerant (BHA), a biologic, is designated by the United States Food and Drug Administration (FDA) as a combination product, containing its core technology of PBM plus B Tri-Calcium Phosphate (B-TCP) an already approved medical device. The company has FDA clearance for a Phase II-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding.
Carmell Corp is a US-based company operating in Biotechnology industry. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 10 full-time employees. The company went IPO on 2021-07-29. Carmell Corporation, formerly Carmell Therapeutics Corporation, is a regenerative medicine platform company. The firm is engaged in the development of allogeneic plasma-based bioactive material (PBM) that is designed to boost innate regenerative pathways across a variety of bone and soft tissue indications. The PBM technology is licensed from Carnegie Mellon University and claims the ability to plasticize whole plasma and cross link with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. Its lead product, CT-101 Bone Healing Accelerant (BHA), a biologic, is designated by the United States Food and Drug Administration (FDA) as a combination product, containing its core technology of PBM plus B Tri-Calcium Phosphate (B-TCP) an already approved medical device. The company has FDA clearance for a Phase II-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding.
